CONTACT US   |  (864) 397-5101

Nephron Pharmaceuticals CEO Lou Kennedy receives honor from USC

Lou Kennedy

The University of South Carolina College of Arts & Sciences Institute for Southern Studies announced on Tuesday that Lou Kennedy, CEO of Nephron Pharmaceuticals in West Columbia, is  the 2023 honoree of the McNair Conversations on the American South.

Kennedy will be interviewed live before an audience at the USC School of Law Karen J. Williams Courtroom for a podcast associated with the event at 6 p.m. Wednesday, March 1, according to a news release. The interview will be done by Mark Smith, the institute’s director.

“I can’t think of anyone more deserving and better suited than Lou Kennedy for this honor,” Smith said. “I look forward to discussing what it takes to succeed in business, in particular at a life sciences company in the aftermath of a once-in-a-lifetime pandemic, with a university alumnus who has proudly supported Carolina and its causes for many years.”

Every year, the Institute for Southern Studies hosts The McNair Conversations on the American South.  Made possible by the generosity of the state’s late Governor RobertMcNair, the McNair Conversations are a live podcast interview honoring people who have made a lasting and significant contribution to the American South.  They are recorded in front of an audience and broadcast on the Institute’s highly successful Take on the South podcast series.

“I am grateful to be recognized by the university I love, and I look forward to joining Dr. Smith and audience participants for a wonderful discussion about all of the great progress South Carolina continues to make,” Kennedy said in the release. “Nephron is a source of pride for me, and I employ many lessons I learned growing up in the American South, and at Carolina, every day as a CEO.”

Join now to enjoy expanded member benefits!

Enjoy exclusive member content, special events, savings, networking and more

Tamia Sumpter

Tamia is a driven senior undergraduate Bioengineering student currently enrolled at Clemson University. With a strong foundation in her field, she has honed her skills through hands-on experience in research and development at Eli Lilly & Company. During her time in the ADME department, Tamia contributed significantly by working on siRNAs and their applications in finding In Vitro-In Vivo Correlation (IVIVC). Looking ahead, Tamia has set her sights on a promising career in law. She aspires to specialize in Intellectual Property Law, with a particular focus on serving as in-house counsel for leading medical device or pharmaceutical companies. Her enthusiasm for this role is palpable as she prepares to embark on her legal journey! She is also a proud member of the Omicron Phi chapter of Delta Sigma Theta Sorority, Inc., PEER Mentor for Clemson PEER/WiSE, and currently serves as the President of Clemson Bioengineering Organization (CBO). With her unique blend of scientific knowledge and legal interests, Tamia is poised to make a meaningful impact in the healthcare and life sciences industries.